JNJ 54416076

Drug Profile

JNJ 54416076

Alternative Names: JNJ-54416076

Latest Information Update: 05 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 31 Oct 2016 Janssen Research & Development plans a phase I exploratory trial in Healthy volunteers in USA (PO, Tablet and Suspension) (NCT02951845)
  • 01 Sep 2016 Janssen Research & Development completes a first-in-human phase I trial in Healthy volunteers in Germany (PO) (NCT02670395)
  • 01 Apr 2016 Phase-I clinical trials in Undefined indication (In volunteers) in Germany (PO, Suspension) (NCT02670395)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top